Monday, November 13, 2017

Secondary CANTOS Analysis IDs Canakinumab Responders

  1. Secondary CANTOS Analysis IDs Canakinumab Responders  Medscape
  2. Novartis launches heart drug counter-offensive  Reuters
  3. AHA: CANTOS Substudy Supports Major Role of Inflammation  MedPage TodayFull coverage

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Headlines